Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

SEC Filings

Form 10-Q
SERES THERAPEUTICS, INC. filed this Form 10-Q on 11/08/2018
Document Outline
Entire Document (4812 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - Seres Therapeutics, Inc.
Page 3 - FORWARD-LOOKING STATEMENTS
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - SERES THERAPEUTICS, INC.
Page 6 - SERES THERAPEUTICS, INC.
Page 7 - SERES THERAPEUTICS, INC.
Page 8 - Unaudited Interim Financial Information
Page 9 - Recently Issued Accounting Standards
Page 10 - Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments
Page 11 - N/A
Page 12 - N/A
Page 13 - Stock Options
Page 14 - Adoption of ASC Topic 606, Revenue from Contracts with Customers
Page 15 - Income Taxes
Page 16 - Collaboration Revenue
Page 17 - Contract Balances from Contracts with Customers
Page 18 - N/A
Page 19 - Leases
Page 20 - N/A
Page 21 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 22 - N/A
Page 23 - Financial Operations Overview
Page 24 - Operating Expenses
Page 25 - General and Administrative Expenses
Page 26 - Other Income (Expense), Net
Page 27 - Revenue from Contracts with Customers (Topic 606),
Page 28 - Comparison of Nine Months Ended September 30, 2018 and 2017
Page 29 - General and Administrative Expenses
Page 30 - Cash Flows
Page 31 - Financing Activities
Page 32 - Contractual Obligations and Commitments
Page 33 - Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Page 34 - PART II - OTHER INFORMATION
Page 35 - Presentation of Financial Statements-Going Concern
Page 36 - Our limited operating history may make it difficult to evaluate the success of our business to date
Page 37 - Our product candidates are based on microbiome therapeutics, which is an unproven approach to therap
Page 38 - N/A
Page 39 - If we experience delays or difficulties in the enrollment of patients in clinical trials, our receip
Page 40 - A Fast Track designation by the FDA may not actually lead to a faster development or regulatory revi
Page 41 - A Breakthrough Therapy designation by the FDA for our product candidates may not lead to a faster de
Page 42 - We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those
Page 43 - We have no experience manufacturing our product candidates at commercial scale, and if we decide to
Page 44 - Risks Related to Commercialization of Our Product Candidates and
Page 45 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 46 - Product liability lawsuits against us could cause us to incur substantial liabilities and limit comm
Page 47 - We may face competition from biosimilars, which may have a material adverse impact on the future com
Page 48 - N/A
Page 49 - Our relationships with customers, physicians and third-party payors will be subject to applicable an
Page 50 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 51 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 52 - Third parties may initiate legal proceedings alleging that we are infringing their intellectual prop
Page 53 - If we are unable to protect the confidentiality of our trade secrets and know-how, our business and
Page 54 - Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our abi
Page 55 - Third parties may initiate legal proceedings alleging that we are infringing their intellectual prop
Page 56 - Issued patents covering our product candidates could be found invalid or unenforceable or could be i
Page 57 - We may be subject to claims by third parties asserting that our employees or we have misappropriated
Page 58 - Risks Related to Our Operations
Page 59 - A variety of risks associated with operating internationally could materially adversely affect our b
Page 60 - Acquisitions or joint ventures could disrupt our business, cause dilution to our stockholders and ot
Page 61 - Comprehensive tax reform bills could adversely affect our business and financial condition.
Page 62 - Our executive officers, directors and principal stockholders, if they choose to act together, have t
Page 63 - If securities or industry analysts issue an adverse or misleading opinion regarding our business, ou
Page 64 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 65 - Item 6. Exhibits.
Page 66 - SIGNATURES
Subdocument 2 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - Policy
Page 3 - EquityOptionPlan
Page 4 - 3.Termination.
Page 5 - Company Obligations upon TerminationSection 3Section 2(e)Section 2(h)Company Arrangementse.g.Section
Page 6 - COBRA
Page 7 - SurvivalSections 59
Page 8 - Change in Control
Page 9 - 8.Parachute Payments.
Page 10 - Section 8
Page 11 - providedhowever
Page 12 - AAA
Page 13 - Specified Employee.
Page 14 - [Signature Page to Employment Agreement]
Page 15 - EXHIBIT A
Page 16 - N/A
Page 17 - Acknowledgment of Waiver of Claims under ADEA
Page 18 - Effective Date
Page 19 - EXHIBIT B
Page 20 - 1.Proprietary Information.
Page 21 - Exhibit AExhibit A
Page 22 - provided further that
Page 23 - 13.Publications and Public Statements
Page 24 - 21.Interpretation
Page 25 - BY SIGNING BELOW, I CERTIFY THAT I HAVE READ THIS AGREEMENT CAREFULLY AND AM SATISFIED THAT I UNDERS
Page 26 - EXHIBIT A
Subdocument 3 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 6 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer